Aier(300015)2023-04-25 16:00Financial Performance - The company's revenue for Q1 2023 reached ¥5,020,539,960.94, representing a 20.44% increase compared to ¥4,168,634,167.01 in the same period last year[4] - Net profit attributable to shareholders was ¥781,064,898.92, up 27.92% from ¥610,600,966.52 year-on-year[4] - Basic earnings per share rose to ¥0.1101, a 25.11% increase from ¥0.0880 in the same period last year[4] - Total operating revenue for Q1 2023 reached CNY 5,020,539,960.94, an increase of 20.5% compared to CNY 4,168,634,167.01 in the same period last year[19] - Net profit attributable to shareholders for Q1 2023 was CNY 1,124,159,535.27, representing a growth of 23.5% year-on-year[19] - The total operating profit for Q1 2023 was approximately CNY 1.15 billion, an increase of 27% compared to CNY 908 million in the same period last year[20] - Net profit for Q1 2023 reached CNY 900.70 million, up 30% from CNY 692.94 million in Q1 2022[20] - The company’s total comprehensive income for Q1 2023 was CNY 915.04 million, up from CNY 663.82 million in Q1 2022[20] Cash Flow and Assets - The net cash flow from operating activities increased by 59.95% to ¥1,653,223,002.26, compared to ¥1,033,576,295.45 in the previous year[4] - Total assets at the end of the reporting period were ¥28,360,189,318.17, reflecting a 6.70% increase from ¥26,578,845,623.29 at the end of the previous year[4] - Cash and cash equivalents at the end of Q1 2023 were CNY 800,000,000.00, down from CNY 900,000,000.00 at the beginning of the year[16] - The total cash and cash equivalents as of March 31, 2023, amounted to CNY 6,562,740,730.97, an increase from CNY 6,004,225,654.40 at the beginning of the year[15] - Accounts receivable increased to CNY 1,784,708,155.11 from CNY 1,583,103,086.31, indicating a rise of 12.7%[16] - Non-current assets totaled CNY 18,068,852,122.86, up from CNY 16,921,630,950.39 at the beginning of the year, marking an increase of 6.8%[17] - The company reported a net increase in cash and cash equivalents of CNY 558.52 million, contrasting with a decrease of CNY 313.02 million in the same quarter last year[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 252,295[10] - The largest shareholder, Aier Medical Investment Group Co., Ltd., holds 34.32% of the shares, totaling 2,463,241,139 shares[10] - The company reported that the number of shares held by the top 10 shareholders includes 2,463,241,139 shares held by the controlling shareholder, Aier Medical Investment Group Co., Ltd.[11] - The company’s actual controller, Chen Bang, holds 79.99% of the shares in the controlling shareholder, Aier Investment[11] - The total number of restricted shares at the beginning of the period was 1,373,477,764, with 45,621 shares released during the period, resulting in an ending balance of 1,373,432,143 restricted shares[14] - There were no new restricted shares added during the reporting period[14] - The company has no shareholders participating in margin financing and securities lending activities among the top 10 shareholders[11] Research and Development - The company reported a 16.40% increase in R&D expenses, totaling ¥66,549,935.52, compared to ¥57,175,077.44 in the previous year[8] - The company reported R&D expenses of CNY 66,549,935.52 for Q1 2023, which is an increase of 16.5% compared to CNY 57,175,077.44 in Q1 2022[19] Future Outlook - The company’s cash flow from operating activities is expected to improve in the upcoming quarters due to increased patient volume and service offerings[15] - The company plans to expand its market presence through new hospital openings and partnerships in the healthcare sector[15] - The company is focusing on the development of new technologies and products to enhance service delivery and patient care[15] - The management provided guidance for the next quarter, anticipating a revenue growth of approximately 15% year-over-year[15] Financial Expenses and Liabilities - Investment income decreased by 83.62% to ¥3,399,520.17 from ¥20,751,408.33 year-on-year[9] - The company experienced a 104.48% increase in financial expenses, amounting to ¥49,079,913.74, primarily due to exchange rate fluctuations[8] - Total liabilities at the end of Q1 2023 were CNY 9,757,834,488.07, compared to CNY 8,963,376,254.16 at the start of the year, reflecting a growth of 8.8%[18] - The cash outflow from investing activities was CNY 1.19 billion, compared to CNY 935.06 million in the same period last year, indicating increased investment activity[23] - The company’s cash flow from financing activities showed a net outflow of CNY 215.26 million, an improvement from a net outflow of CNY 487.56 million in the previous year[23]